• 4 May 2015

    Sonendo®, Inc., the developer of a transformative technology for the endodontic marketplace, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the third generation of its Multisonic UltracleaningTM System for root canal therapy. This recent 510(k) clearance expands the use for the GentleWaveTM System to include anterior and pre-molar cases in addition to the current molar indication. The system is designed to be a minimally-invasive, disruptive technology that utilizes multiple wavelengths of sound to clean the entire root canal system simultaneously.

  • 16 April 2015

    Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company’s ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver (EASL), or the 50th International Liver Congress 2015, taking place in Vienna April 22-26. The poster, titled “WTX101-201: Phase 2 Study of Bis-choline Tetrathiomolybdate in Newly Diagnosed Wilson Disease Patients,” will be presented in the Clinical Trials in Progress session on April 25.

  • 16 April 2015

    Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system. 

  • 19 March 2015

    Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has published positive Phase 2b clinical data for its novel TrkA kinase inhibitor CT327 in Acta Dermato-Venereologica, one of the pre-eminent international peer-review journals in dermatology.

  • 5 February 2015

    InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.